English
English Indonesia Türkçe Deutsch Español Português Pусский Français Italiano Nederlands Polski العربية ไทย Tiếng Việt 繁體中文 简体中文 日本語 한국어
diegoadiazg's profile picture. Medical Oncologist • Thoracic Oncology @incanMX alum | #CánCare • Hosp. Ángeles del Carmen | Views my own

Diego A. Díaz-García

@diegoadiazg

Medical Oncologist • Thoracic Oncology @incanMX alum | #CánCare • Hosp. Ángeles del Carmen | Views my own

2KPosts 2KFollowers 1KFollowing
You might like
diegoadiazg's profile picture.
Diego A. Díaz-García
@diegoadiazg
Nov 6

🧔🏻‍♂️ Age and Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer. Meta-analysis of 11 ph3 trials (n=13,648) in mHSPC: treatment intensification improved OS (HR 0.73), but benefit was smaller in men ≥70 yrs (HR 0.82 vs 0.63 <70). In older pts, triplet therapy…

diegoadiazg's tweet image. 🧔🏻‍♂️ Age and Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer. Meta-analysis of 11 ph3 trials (n=13,648) in mHSPC: treatment intensification improved OS (HR 0.73), but benefit was smaller in men ≥70 yrs (HR 0.82 vs 0.63 &amp;lt;70). In older pts, triplet therapy…
diegoadiazg's tweet image. 🧔🏻‍♂️ Age and Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer. Meta-analysis of 11 ph3 trials (n=13,648) in mHSPC: treatment intensification improved OS (HR 0.73), but benefit was smaller in men ≥70 yrs (HR 0.82 vs 0.63 &amp;lt;70). In older pts, triplet therapy…
diegoadiazg's tweet image. 🧔🏻‍♂️ Age and Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer. Meta-analysis of 11 ph3 trials (n=13,648) in mHSPC: treatment intensification improved OS (HR 0.73), but benefit was smaller in men ≥70 yrs (HR 0.82 vs 0.63 &amp;lt;70). In older pts, triplet therapy…
1
2
6
3
332
diegoadiazg's profile picture.
Diego A. Díaz-García
@diegoadiazg
Nov 6

👨🏼‍🦳 European Study of Prostate Cancer Screening, 23-Year Follow-up. After 23 years of follow-up, the ERSPC trial reports a 13% reduction in prostate cancer mortality with PSA-based screening (RR 0.87). One death prevented per 456 men screened, with an improved harm–benefit ratio.…

diegoadiazg's tweet image. 👨🏼‍🦳 European Study of Prostate Cancer Screening, 23-Year Follow-up. After 23 years of follow-up, the ERSPC trial reports a 13% reduction in prostate cancer mortality with PSA-based screening (RR 0.87). One death prevented per 456 men screened, with an improved harm–benefit ratio.…
diegoadiazg's tweet image. 👨🏼‍🦳 European Study of Prostate Cancer Screening, 23-Year Follow-up. After 23 years of follow-up, the ERSPC trial reports a 13% reduction in prostate cancer mortality with PSA-based screening (RR 0.87). One death prevented per 456 men screened, with an improved harm–benefit ratio.…
0
2
5
0
290
diegoadiazg's profile picture.
Diego A. Díaz-García
@diegoadiazg
Nov 6

👨 Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. #EMBARK In high-risk biochemically recurrent prostate cancer, enzalutamide + leuprolide improved 8-year OS vs leuprolide alone (78.9% vs 69.5%; HR 0.60; P<0.001). Enzalutamide monotherapy showed…

diegoadiazg's tweet image. 👨 Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. #EMBARK In high-risk biochemically recurrent prostate cancer, enzalutamide + leuprolide improved 8-year OS vs leuprolide alone (78.9% vs 69.5%; HR 0.60; P&amp;lt;0.001). Enzalutamide monotherapy showed…
diegoadiazg's tweet image. 👨 Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. #EMBARK In high-risk biochemically recurrent prostate cancer, enzalutamide + leuprolide improved 8-year OS vs leuprolide alone (78.9% vs 69.5%; HR 0.60; P&amp;lt;0.001). Enzalutamide monotherapy showed…
diegoadiazg's tweet image. 👨 Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. #EMBARK In high-risk biochemically recurrent prostate cancer, enzalutamide + leuprolide improved 8-year OS vs leuprolide alone (78.9% vs 69.5%; HR 0.60; P&amp;lt;0.001). Enzalutamide monotherapy showed…
0
0
1
0
157
diegoadiazg's profile picture.
Diego A. Díaz-García
@diegoadiazg
Nov 4

🎯 FLAURA2: Osimertinib + chemo in EGFRmut advanced NSCLC. First-line osimertinib plus platinum–pemetrexed significantly improved OS vs osimertinib alone (47.5 vs 37.6 months; HR 0.77, p=0.02). Toxicities were higher but manageable, reinforcing combo as a new SOC. 📖 @NEJM…

diegoadiazg's tweet image. 🎯 FLAURA2: Osimertinib + chemo in EGFRmut advanced NSCLC. First-line osimertinib plus platinum–pemetrexed significantly improved OS vs osimertinib alone (47.5 vs 37.6 months; HR 0.77, p=0.02). Toxicities were higher but manageable, reinforcing combo as a new SOC. 📖 @NEJM…
diegoadiazg's tweet image. 🎯 FLAURA2: Osimertinib + chemo in EGFRmut advanced NSCLC. First-line osimertinib plus platinum–pemetrexed significantly improved OS vs osimertinib alone (47.5 vs 37.6 months; HR 0.77, p=0.02). Toxicities were higher but manageable, reinforcing combo as a new SOC. 📖 @NEJM…
diegoadiazg's tweet image. 🎯 FLAURA2: Osimertinib + chemo in EGFRmut advanced NSCLC. First-line osimertinib plus platinum–pemetrexed significantly improved OS vs osimertinib alone (47.5 vs 37.6 months; HR 0.77, p=0.02). Toxicities were higher but manageable, reinforcing combo as a new SOC. 📖 @NEJM…
2
6
30
10
2K
diegoadiazg's profile picture.
Diego A. Díaz-García
@diegoadiazg
Nov 4

🎯 MARIPOSA: Amivantamab–Lazertinib in EGFRm NSCLC. In 1L EGFR-mutated advanced NSCLC, amivantamab–lazertinib significantly improved OS vs osimertinib (HR 0.75; 3-yr OS 60% vs 51%). Confirms the value of dual EGFR–MET inhibition in this setting. 📖 @NEJM DOI 👉🏻…

diegoadiazg's tweet image. 🎯 MARIPOSA: Amivantamab–Lazertinib in EGFRm NSCLC. In 1L EGFR-mutated advanced NSCLC, amivantamab–lazertinib significantly improved OS vs osimertinib (HR 0.75; 3-yr OS 60% vs 51%). Confirms the value of dual EGFR–MET inhibition in this setting. 📖 @NEJM DOI 👉🏻…
diegoadiazg's tweet image. 🎯 MARIPOSA: Amivantamab–Lazertinib in EGFRm NSCLC. In 1L EGFR-mutated advanced NSCLC, amivantamab–lazertinib significantly improved OS vs osimertinib (HR 0.75; 3-yr OS 60% vs 51%). Confirms the value of dual EGFR–MET inhibition in this setting. 📖 @NEJM DOI 👉🏻…
diegoadiazg's tweet image. 🎯 MARIPOSA: Amivantamab–Lazertinib in EGFRm NSCLC. In 1L EGFR-mutated advanced NSCLC, amivantamab–lazertinib significantly improved OS vs osimertinib (HR 0.75; 3-yr OS 60% vs 51%). Confirms the value of dual EGFR–MET inhibition in this setting. 📖 @NEJM DOI 👉🏻…
diegoadiazg's tweet image. 🎯 MARIPOSA: Amivantamab–Lazertinib in EGFRm NSCLC. In 1L EGFR-mutated advanced NSCLC, amivantamab–lazertinib significantly improved OS vs osimertinib (HR 0.75; 3-yr OS 60% vs 51%). Confirms the value of dual EGFR–MET inhibition in this setting. 📖 @NEJM DOI 👉🏻…
2
8
49
15
3K
diegoadiazg's profile picture.
Diego A. Díaz-García
@diegoadiazg
Nov 3

🫁 Lung Cancer in Nonsmokers: A Distinct Entity. Accounts for 15–20% of global cases, often harboring targetable EGFR (43%) or ALK (12%) alterations. With TKIs, median survival in advanced disease can exceed 3–5 years, highlighting major gains from precision oncology. 📖…

diegoadiazg's tweet image. 🫁 Lung Cancer in Nonsmokers: A Distinct Entity. Accounts for 15–20% of global cases, often harboring targetable EGFR (43%) or ALK (12%) alterations. With TKIs, median survival in advanced disease can exceed 3–5 years, highlighting major gains from precision oncology. 📖…
diegoadiazg's tweet image. 🫁 Lung Cancer in Nonsmokers: A Distinct Entity. Accounts for 15–20% of global cases, often harboring targetable EGFR (43%) or ALK (12%) alterations. With TKIs, median survival in advanced disease can exceed 3–5 years, highlighting major gains from precision oncology. 📖…
0
4
11
4
738
diegoadiazg's profile picture.
Diego A. Díaz-García
@diegoadiazg
Nov 2

🧠 Clear communication improves care. Use numbers, not vague terms like rare or unlikely; keep denominators consistent; discuss absolute risks; and add context. 📖 @JAMA_current 👉🏻 jamanetwork.com/journals/jama/… #CánCare #oncology #nsclc #lcsm

diegoadiazg's tweet image. 🧠 Clear communication improves care. Use numbers, not vague terms like rare or unlikely; keep denominators consistent; discuss absolute risks; and add context. 📖 @JAMA_current 👉🏻 jamanetwork.com/journals/jama/… #CánCare #oncology #nsclc #lcsm
0
3
4
0
417
diegoadiazg's profile picture.
Diego A. Díaz-García
@diegoadiazg
Nov 2

🫁 ALEX final OS analysis. In advanced ALK+ NSCLC, alectinib achieved a median OS of 81.1 vs 54.2 months with crizotinib (HR 0.78; 95% CI 0.56-1.08), consistent benefit across CNS subgroups, and sustained safety. 📖 @Annals_Oncology @peters_solange @TonyMok9 DOI 👉🏻…

diegoadiazg's tweet image. 🫁 ALEX final OS analysis. In advanced ALK+ NSCLC, alectinib achieved a median OS of 81.1 vs 54.2 months with crizotinib (HR 0.78; 95% CI 0.56-1.08), consistent benefit across CNS subgroups, and sustained safety. 📖 @Annals_Oncology @peters_solange @TonyMok9 DOI 👉🏻…
diegoadiazg's tweet image. 🫁 ALEX final OS analysis. In advanced ALK+ NSCLC, alectinib achieved a median OS of 81.1 vs 54.2 months with crizotinib (HR 0.78; 95% CI 0.56-1.08), consistent benefit across CNS subgroups, and sustained safety. 📖 @Annals_Oncology @peters_solange @TonyMok9 DOI 👉🏻…
diegoadiazg's tweet image. 🫁 ALEX final OS analysis. In advanced ALK+ NSCLC, alectinib achieved a median OS of 81.1 vs 54.2 months with crizotinib (HR 0.78; 95% CI 0.56-1.08), consistent benefit across CNS subgroups, and sustained safety. 📖 @Annals_Oncology @peters_solange @TonyMok9 DOI 👉🏻…
0
4
23
11
3K
Diego A. Díaz-García reposted
Larvol's profile picture.
LARVOL
@Larvol
Oct 22

Top Lung Cancer Oncologists from @myESMO 2025 Explore more insights and data from #ESMO25: t.ly/yDvnj #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #MedicalOncology #ESMO2025 #LungCancer | @StephenVLiu | @HHorinouchi | @Tony_Calles…

Larvol's tweet image. Top Lung Cancer Oncologists from @myESMO 2025 Explore more insights and data from #ESMO25: t.ly/yDvnj #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #MedicalOncology #ESMO2025 #LungCancer | @StephenVLiu | @HHorinouchi | @Tony_Calles…
0
14
27
3
2K
diegoadiazg's profile picture.
Diego A. Díaz-García
@diegoadiazg
Oct 19

🫁 Ivonescimab + chemo vs tislelizumab + chemo in stage IIIB–IV sqNSCLC. #HARMONi-6 @myESMO Ivonescimab significantly improved PFS: 11.1 vs 6.9 mo (HR 0.60, p<0.0001), showing consistent benefit across PD-L1 subgroups with manageable safety. Could this dual-target antibody…

diegoadiazg's tweet image. 🫁 Ivonescimab + chemo vs tislelizumab + chemo in stage IIIB–IV sqNSCLC. #HARMONi-6 @myESMO Ivonescimab significantly improved PFS: 11.1 vs 6.9 mo (HR 0.60, p&amp;lt;0.0001), showing consistent benefit across PD-L1 subgroups with manageable safety. Could this dual-target antibody…
diegoadiazg's tweet image. 🫁 Ivonescimab + chemo vs tislelizumab + chemo in stage IIIB–IV sqNSCLC. #HARMONi-6 @myESMO Ivonescimab significantly improved PFS: 11.1 vs 6.9 mo (HR 0.60, p&amp;lt;0.0001), showing consistent benefit across PD-L1 subgroups with manageable safety. Could this dual-target antibody…
diegoadiazg's tweet image. 🫁 Ivonescimab + chemo vs tislelizumab + chemo in stage IIIB–IV sqNSCLC. #HARMONi-6 @myESMO Ivonescimab significantly improved PFS: 11.1 vs 6.9 mo (HR 0.60, p&amp;lt;0.0001), showing consistent benefit across PD-L1 subgroups with manageable safety. Could this dual-target antibody…
diegoadiazg's tweet image. 🫁 Ivonescimab + chemo vs tislelizumab + chemo in stage IIIB–IV sqNSCLC. #HARMONi-6 @myESMO Ivonescimab significantly improved PFS: 11.1 vs 6.9 mo (HR 0.60, p&amp;lt;0.0001), showing consistent benefit across PD-L1 subgroups with manageable safety. Could this dual-target antibody…
0
6
14
7
1K
diegoadiazg's profile picture.
Diego A. Díaz-García
@diegoadiazg
Oct 19

🫁 Sacituzumab-tmt: A new SoC for EGFR-TKI–resistant NSCLC? #OptiTROP-Lung04 The first TROP2 ADC to show significant PFS and OS benefits vs platinum chemo, with fewer serious AEs (7.4% vs 17%) and no ILD. Could this redefine post-TKI therapy sequencing? Will this become a…

diegoadiazg's tweet image. 🫁 Sacituzumab-tmt: A new SoC for EGFR-TKI–resistant NSCLC? #OptiTROP-Lung04 The first TROP2 ADC to show significant PFS and OS benefits vs platinum chemo, with fewer serious AEs (7.4% vs 17%) and no ILD. Could this redefine post-TKI therapy sequencing? Will this become a…
diegoadiazg's tweet image. 🫁 Sacituzumab-tmt: A new SoC for EGFR-TKI–resistant NSCLC? #OptiTROP-Lung04 The first TROP2 ADC to show significant PFS and OS benefits vs platinum chemo, with fewer serious AEs (7.4% vs 17%) and no ILD. Could this redefine post-TKI therapy sequencing? Will this become a…
diegoadiazg's tweet image. 🫁 Sacituzumab-tmt: A new SoC for EGFR-TKI–resistant NSCLC? #OptiTROP-Lung04 The first TROP2 ADC to show significant PFS and OS benefits vs platinum chemo, with fewer serious AEs (7.4% vs 17%) and no ILD. Could this redefine post-TKI therapy sequencing? Will this become a…
diegoadiazg's tweet image. 🫁 Sacituzumab-tmt: A new SoC for EGFR-TKI–resistant NSCLC? #OptiTROP-Lung04 The first TROP2 ADC to show significant PFS and OS benefits vs platinum chemo, with fewer serious AEs (7.4% vs 17%) and no ILD. Could this redefine post-TKI therapy sequencing? Will this become a…
1
2
12
12
992
diegoadiazg's profile picture.
Diego A. Díaz-García
@diegoadiazg
Oct 18

🫁 Atezo + Tira vs Durva in unresectable stage III NSCLC. @myESMO In PD-L1+ pts, median PFS was 19.4 vs 16.6 mo (HR 0.96); OS similar (not estimable vs 54.8 mo). ❌ No added benefit with atezo + tira vs durva; safety profiles consistent with previous data. #CánCare #NSCLC…

diegoadiazg's tweet image. 🫁 Atezo + Tira vs Durva in unresectable stage III NSCLC. @myESMO In PD-L1+ pts, median PFS was 19.4 vs 16.6 mo (HR 0.96); OS similar (not estimable vs 54.8 mo). ❌ No added benefit with atezo + tira vs durva; safety profiles consistent with previous data. #CánCare #NSCLC…
diegoadiazg's tweet image. 🫁 Atezo + Tira vs Durva in unresectable stage III NSCLC. @myESMO In PD-L1+ pts, median PFS was 19.4 vs 16.6 mo (HR 0.96); OS similar (not estimable vs 54.8 mo). ❌ No added benefit with atezo + tira vs durva; safety profiles consistent with previous data. #CánCare #NSCLC…
diegoadiazg's tweet image. 🫁 Atezo + Tira vs Durva in unresectable stage III NSCLC. @myESMO In PD-L1+ pts, median PFS was 19.4 vs 16.6 mo (HR 0.96); OS similar (not estimable vs 54.8 mo). ❌ No added benefit with atezo + tira vs durva; safety profiles consistent with previous data. #CánCare #NSCLC…
0
0
1
1
181
diegoadiazg's profile picture.
Diego A. Díaz-García
@diegoadiazg
Oct 18

🫁 MDT-BRIDGE @MartinReck2 @myESMO In stage IIB–select IIIB NSCLC, close MDT reassessment during neoadjuvant durvalumab + chemo enabled local treatment in 95% of pts. Resection rate 85.7% (94% R0), pCR 27.6%. Outcomes consistent with AEGEAN, even including borderline…

diegoadiazg's tweet image. 🫁 MDT-BRIDGE @MartinReck2 @myESMO In stage IIB–select IIIB NSCLC, close MDT reassessment during neoadjuvant durvalumab + chemo enabled local treatment in 95% of pts. Resection rate 85.7% (94% R0), pCR 27.6%. Outcomes consistent with AEGEAN, even including borderline…
diegoadiazg's tweet image. 🫁 MDT-BRIDGE @MartinReck2 @myESMO In stage IIB–select IIIB NSCLC, close MDT reassessment during neoadjuvant durvalumab + chemo enabled local treatment in 95% of pts. Resection rate 85.7% (94% R0), pCR 27.6%. Outcomes consistent with AEGEAN, even including borderline…
diegoadiazg's tweet image. 🫁 MDT-BRIDGE @MartinReck2 @myESMO In stage IIB–select IIIB NSCLC, close MDT reassessment during neoadjuvant durvalumab + chemo enabled local treatment in 95% of pts. Resection rate 85.7% (94% R0), pCR 27.6%. Outcomes consistent with AEGEAN, even including borderline…
diegoadiazg's tweet image. 🫁 MDT-BRIDGE @MartinReck2 @myESMO In stage IIB–select IIIB NSCLC, close MDT reassessment during neoadjuvant durvalumab + chemo enabled local treatment in 95% of pts. Resection rate 85.7% (94% R0), pCR 27.6%. Outcomes consistent with AEGEAN, even including borderline…
1
9
31
15
3K
diegoadiazg's profile picture.
Diego A. Díaz-García
@diegoadiazg
Oct 18

🫁 DeLLphi-303: tarlatamab + 1L CT-IO in ES-SCLC. @myESMO Promising efficacy 👉🏻 ORR 71%, mPFS 9 mo, 12-mo OS 81%. CRS events mostly low grade. Supports ongoing phase III DeLLphi-312 trial. #ESMO25 #CánCare #SCLC #lcsm #Tarlatamab

diegoadiazg's tweet image. 🫁 DeLLphi-303: tarlatamab + 1L CT-IO in ES-SCLC. @myESMO Promising efficacy 👉🏻 ORR 71%, mPFS 9 mo, 12-mo OS 81%. CRS events mostly low grade. Supports ongoing phase III DeLLphi-312 trial. #ESMO25 #CánCare #SCLC #lcsm #Tarlatamab
diegoadiazg's tweet image. 🫁 DeLLphi-303: tarlatamab + 1L CT-IO in ES-SCLC. @myESMO Promising efficacy 👉🏻 ORR 71%, mPFS 9 mo, 12-mo OS 81%. CRS events mostly low grade. Supports ongoing phase III DeLLphi-312 trial. #ESMO25 #CánCare #SCLC #lcsm #Tarlatamab
diegoadiazg's tweet image. 🫁 DeLLphi-303: tarlatamab + 1L CT-IO in ES-SCLC. @myESMO Promising efficacy 👉🏻 ORR 71%, mPFS 9 mo, 12-mo OS 81%. CRS events mostly low grade. Supports ongoing phase III DeLLphi-312 trial. #ESMO25 #CánCare #SCLC #lcsm #Tarlatamab
diegoadiazg's tweet image. 🫁 DeLLphi-303: tarlatamab + 1L CT-IO in ES-SCLC. @myESMO Promising efficacy 👉🏻 ORR 71%, mPFS 9 mo, 12-mo OS 81%. CRS events mostly low grade. Supports ongoing phase III DeLLphi-312 trial. #ESMO25 #CánCare #SCLC #lcsm #Tarlatamab
1
7
23
8
1K
diegoadiazg's profile picture.
Diego A. Díaz-García
@diegoadiazg
Oct 18

🫁 Chemo-IO + Durvalumab and Ceralasertib in ES-SCLC. @myESMO In treatment-naïve ES-SCLC, CT-IO followed by durvalumab + ceralasertib achieved: 🔹ORR 73% 🔹mPFS 6.1 mo 🔹12-/24-mo OS rates of 68%/59%. Encouraging results beyond durvalumab maintenance alone. #ESMO25 #CánCare…

diegoadiazg's tweet image. 🫁 Chemo-IO + Durvalumab and Ceralasertib in ES-SCLC. @myESMO In treatment-naïve ES-SCLC, CT-IO followed by durvalumab + ceralasertib achieved: 🔹ORR 73% 🔹mPFS 6.1 mo 🔹12-/24-mo OS rates of 68%/59%. Encouraging results beyond durvalumab maintenance alone. #ESMO25 #CánCare…
diegoadiazg's tweet image. 🫁 Chemo-IO + Durvalumab and Ceralasertib in ES-SCLC. @myESMO In treatment-naïve ES-SCLC, CT-IO followed by durvalumab + ceralasertib achieved: 🔹ORR 73% 🔹mPFS 6.1 mo 🔹12-/24-mo OS rates of 68%/59%. Encouraging results beyond durvalumab maintenance alone. #ESMO25 #CánCare…
diegoadiazg's tweet image. 🫁 Chemo-IO + Durvalumab and Ceralasertib in ES-SCLC. @myESMO In treatment-naïve ES-SCLC, CT-IO followed by durvalumab + ceralasertib achieved: 🔹ORR 73% 🔹mPFS 6.1 mo 🔹12-/24-mo OS rates of 68%/59%. Encouraging results beyond durvalumab maintenance alone. #ESMO25 #CánCare…
diegoadiazg's tweet image. 🫁 Chemo-IO + Durvalumab and Ceralasertib in ES-SCLC. @myESMO In treatment-naïve ES-SCLC, CT-IO followed by durvalumab + ceralasertib achieved: 🔹ORR 73% 🔹mPFS 6.1 mo 🔹12-/24-mo OS rates of 68%/59%. Encouraging results beyond durvalumab maintenance alone. #ESMO25 #CánCare…
0
4
8
7
480
ogarrieta's profile picture. Head of the Thoracic Oncology Unit @utoracica and the Personalized Medicine Lab, Instituto Nacional de Cancerología 🇲🇽 @incanmx, Medicine Professor @UNAM_MX

Oscar Arrieta

@ogarrieta
JonathanNefro's profile picture. Nefrólogo en Hospital Civil de Guadalajara y Profesor en la Escuela de Medicina de la Universidad de Guadalajara

Jonathan Chávez

@JonathanNefro
StephenVLiu's profile picture. Thoracic Oncologist, Chief of Heme/Onc @Georgetown University; Head of Developmental Therapeutics @LombardiCancer; Co-Chair #DCLung26 & #TexasLung26; #HereWeGo

Stephen V Liu, MD

@StephenVLiu
AndresFCardonaZ's profile picture. Pursue knowledge, mentor students, collaborate globally, and push boundaries. Everything else is just noise in the academic concert.

Andres F. Cardona

@AndresFCardonaZ
UToracica's profile picture. Cuenta oficial del Departamento de Oncología Torácica del Instituto Nacional de Cancerológia de México

UFOT INCan

@UToracica
Dr_Ivanoncologo's profile picture. Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla. Cancer treatment must be personalized to the individual needs of the patient.

Dr. Iván R. González

@Dr_Ivanoncologo
HerediaOncologo's profile picture. Oncologo médico. Oncólogo torácico. #INCan 🇲🇽 🫁 Hospital Punta Médica. Candidato SNI. Investigador en ensayos clínicos de cáncer de pulmón.

David Heredia.

@HerediaOncologo
IASLC's profile picture. The International Association for the Study of Lung Cancer is the only global organization dedicated solely to the study of lung cancer. #LCSM

IASLC

@IASLC
andie1306's profile picture. Anestesiología • Música

Señorita Ketamina

@andie1306
IniguezMon's profile picture. Above us only sky. Lo que me gusta le tomo foto.

Mónica

@IniguezMon
PleuralPOCUS's profile picture. Especialista en Enfermedades Respiratorias y Pleurales - Coordinador de Unidad de Medicina Pleural de Occidente

Alejandro

@PleuralPOCUS
ChristianRolfo's profile picture. Director Division of Medical Oncology. Assoc Director Early Phase Clinical Trials The James Comprehensive Cancer Center. Prof. The OSU.Liquid Biopsy T/RT my own

Christian Rolfo

@ChristianRolfo
GRecondoMD's profile picture. MD PhD | Medical Oncologist | Executive Director - Global Development Lead @Amgen | Views expressed are my own

Gonzalo Recondo

@GRecondoMD
LuciaViola9's profile picture. Interventional Pulmonologist- Head of Thoracic Oncology Service. Fundación Neumológica Colombiana - Fundación CTIC. Contacto consultoriopulmonar@gmail.com

Lucia Viola MD

@LuciaViola9
mtzsaid's profile picture. Surgical Oncologist at NCI Mexico (INCan) & Médica Sur. LASSO founder President & @SMeO past President. Wine lover. MPP in progress.

Hector Martinez Said

@mtzsaid
Latinamd's profile picture. Associate Director Community Outreach- 🫁Thoracic Oncology, University of Miami @SylvesterCancer , 🇵🇷Boricua, Co-founder @KidsHelpingKidsSucceed

Dr. Estela Rodriguez

@Latinamd
dralanreyesonco's profile picture. Medical Oncologist/ Int Medicine 🩺🧬🦀. Board Certified @TecdeMonterrey & @cuccuanl

Alan Reyes-M.D

@dralanreyesonco
DSG_MD's profile picture. MD, MSc 💜 Clinical oncology. Translational research, building patient relations 👥. Students are the best teachers.

Daniela Shveid Gerson

@DSG_MD
oncologician's profile picture. Masters of molecular oncology (CNIO ) Medical Oncologist by profession (Lung is close to my heart), researcher by passion, precision oncology,liquid biopsy.

Nirmal Raut

@oncologician
v1nart3's profile picture.

Arturo Vega

@v1nart3
RmagicianNighte's profile picture. 024 25_165_95 0M

夜落星河

@RmagicianNighte
NZ5g94uu2iN38's profile picture.

PhoenixHuntington

@NZ5g94uu2iN38
aakkii96990188's profile picture.

aakkii

@aakkii96990188
RonaldDomingue1's profile picture. Internist/Medical Oncologist

Ronald Dominguez M. MD

@RonaldDomingue1
TornikeZaba's profile picture. PGY1 IM at Boston Medical Center—Brighton ESMO exam certificate 2023

Tornike Zabakhidze

@TornikeZaba
harassue_lk's profile picture. 肺癌関連のまとめ。1日1論文呟きます。

勉強用

@harassue_lk
Amaaaan9999's profile picture.

aman mujawar

@Amaaaan9999
NickTellez1992's profile picture. Internal medicine PUJ; Master student Molecular Oncology CEB; Oncology Fellowship USanitas.

Nicolás Téllez Castillo

@NickTellez1992
NavedaM_'s profile picture.

MN

@NavedaM_
RohitBanwar's profile picture. Medical Oncologist, Asst Professor @UVMMedCenter; alum editorial fellow@JCO_ASCO; member @ASCOTECAG. Immuno-Oncology, thoracic Oncology, Melanoma

Rohit Singh, MD

@RohitBanwar
mayluciemeyer's profile picture. Swiss medical oncologist, trained in Paris (go PSG) and NY (go Trader Joe)

Meyer May-Lucie

@mayluciemeyer
Psy_Lyonnaise's profile picture. Psy en hospitalier & libéral. EMDR/TRAUMA. Enseigne Psychopathologie & Psychologie du développement. Pdte Association d'Aide Psy Etudiants #AcselPsy (2017)

Souad Cousinier 🇨🇵🇪🇺

@Psy_Lyonnaise
tt5390's profile picture. 30代外科医。

znnyo

@tt5390
Wasim1846's profile picture. Medical oncologist , love Arsenal, ⚽⚽ and travelling

wasim

@Wasim1846
jakefreshy43's profile picture. We need to unite with peace and love, not hate and violence. I walk with the all righteous, the all loving and all powerful God🇺🇾🇮🇱🇯🇵🇵🇸🇷🇺🇺🇦🇺🇸✝️

fresh francis

@jakefreshy43
AdambrooksCom's profile picture.

Adam Brooks

@AdambrooksCom
Joseph___Hawa's profile picture. HSBC Deputy Manager at HSBC Bank Former Account Officer at HSBC Senior Financial Accountant From Jeddah, Saudi Arabia Lives in London, United Kingdom

Joseph Hawa

@Joseph___Hawa
hartselle212625's profile picture. If🤮 you haven't made a profit💩 in the investment market yet, please click the link🙂 to contact us an😕🦧d our 🤨professional team will h🤮elp you make a profit.

hartselle28441

@hartselle212625
VacaEdgardo's profile picture. Padre, Ginecólogo, Deportista, Geek, caja de Pandora...

Edgardo Vaca

@VacaEdgardo
rosalind52011's profile picture. A passionate girl who loves exploring the world. I've been to over fifty countries and continue to discover new sights. 🐶 Loves dogs ✈️ Obsessed with travel 💖

Rosalind Ainsley

@rosalind52011
ronaldonobregMD's profile picture. 5th-year Med Student | USMLE | Research Fellow | Student Member, American College of Cardiology (@ACCinTouch) | 🇧🇷 🇺🇸

Ronaldo Nóbrega

@ronaldonobregMD
nDanuPrime's profile picture. The world is an illusion. Based on the vision of one animal.

Dasun Nawanjana

@nDanuPrime
Tuitssobrecanc1's profile picture. 🇲🇽 Medical Oncologist @ABCcentromedico Molecular Oncology @CNIOStopCancer @ceb_edu & @ESOncology based interest in Molecular insights in cancer patients

@GabrielaRegalado-Porras

@Tuitssobrecanc1
JuanPaMeraJ's profile picture. | RadiationOncology PGY2 #RadOnc | Palliative Care MsC.

JuanPa Mera

@JuanPaMeraJ
batoune21's profile picture.

baptiste Boulet

@batoune21
marianne_diehl's profile picture.

Marianne Diehl

@marianne_diehl
ElRetoso's profile picture. https://t.co/759qUBoe13

EL RETOSO

@ElRetoso
RashmiJKumar's profile picture. General Surgery resident @UMichSurgery | Alum of @UNCmdphd and Univ of Pitt @PittTweet | Aspiring Surgeon-Scientist | is 🇮🇳+🇺🇸 |

Rashmi Kumar, MD, PhD

@RashmiJKumar
FTHWU's profile picture. Thoracic Medical Oncology Fellow @pmcancercentre , supported by the @UBC Clinician Investigator Program

Florence T.H. Wu

@FTHWU
elvintanriverd's profile picture. General Surgery- Surgical Oncology +994102358482 , +905352348482 elvintanriverdi.dr@gmail.com

OP.DR.ELVIN TANRIVERDI

@elvintanriverd
KamalThippu's profile picture. Clinical/Rad Oncologist @CUH_NHS @TeamQEH @GenesisCare l Affiliated Asst Prof @Cambridge_Uni @CRUKCamRadNet l Cancer Researcher I Asst Editor @ClinOncology

Dr Kamal Thippu MD FRCR

@KamalThippu
TurakTuncay's profile picture.

tuncay turak

@TurakTuncay
Arwakmbs's profile picture.

هاوي✨

@Arwakmbs
AngelaDias14's profile picture.

Angela Dias

@AngelaDias14
_Caio_CCP's profile picture.

CCP

@_Caio_CCP
alenosfra's profile picture.

Alvaro E. Osorio F.

@alenosfra
dilara_rx's profile picture.

Dilara

@dilara_rx
ShakeKumarMD's profile picture. Radiation Oncologist @OncologyInst| formerly trained at @DukeRadOnc | @Duke undergrad alum |

Abhishek ("Shake") Kumar, MD MAS

@ShakeKumarMD
DrJNaidoo's profile picture. Professor of Medical Oncology @CancerCentreIre | Thoracic Oncologist | Immunotherapy & Immune toxicity | Adjunct faculty Johns Hopkins University

Jarushka Naidoo

@DrJNaidoo
GGene78392's profile picture. Love and reason guide me ❤️🧠The North’s light doesn’t reach my heart, but I’m here ☀️❤️🇺🇸 Health is a daily attitude, not a destination

Alice Caron

@GGene78392
anusocool's profile picture.

anusha.tummala

@anusocool
mrugaldoshi's profile picture. D.M.Medical Oncology | M.D.Medicine |

Mrugal Doshi

@mrugaldoshi
DjilaliDjila10's profile picture. oncology doctor

benaissa Djilali

@DjilaliDjila10
stephaniejohng's profile picture. PGY3 @MGUHRadOnc ☢️ @GUH_WHCSurgRes • @GUMedicine

Stephanie Johng, MD

@stephaniejohng
giusvisc's profile picture. MD, PhD. Lung Medical Oncologist at Monaldi Hospital in Naples. AIOM Giovani WG. Fighting against the emperor of all maladies.

giuseppe viscardi

@giusvisc
MuhammadSolaim2's profile picture.

Muhammad Solaiman

@MuhammadSolaim2
AmithaKamath1's profile picture.

Amitha Kamath

@AmithaKamath1
MDmanishshah's profile picture. Oncologist and Researcher. #CureCancer https://t.co/mWwmvvuQ6q CancerCast Podcast - https://t.co/QQtwvBzB6n

Manish A Shah

@MDmanishshah
miss_zeth's profile picture.

Zero

@miss_zeth
KabalaZineb's profile picture.

kabala zineb

@KabalaZineb
doctormacias's profile picture. Internal medicine and infections doctor. Former 2009 Pandemic Influenza Tzar in Mexico. National Research System (SNI) Level 3. Opinions, mine.

Alejandro Macias

@doctormacias
ogarrieta's profile picture. Head of the Thoracic Oncology Unit @utoracica and the Personalized Medicine Lab, Instituto Nacional de Cancerología 🇲🇽 @incanmx, Medicine Professor @UNAM_MX

Oscar Arrieta

@ogarrieta
CLICaP_'s profile picture. Latin American Consortium for Lung Cancer Reserch-CLICaP/ Non-profit organization that promotes clinical and traslational reserarch on Thoracic Oncology

CLICaP

@CLICaP_
VivekSubbiah's profile picture. Chief, Early-Phase Drug Development|@SarahCannonDocs #Oncologist, #Phase1trials, #PrecisionMedicine. Tweets=My own.

Vivek Subbiah, MD

@VivekSubbiah
JonathanNefro's profile picture. Nefrólogo en Hospital Civil de Guadalajara y Profesor en la Escuela de Medicina de la Universidad de Guadalajara

Jonathan Chávez

@JonathanNefro
StephenVLiu's profile picture. Thoracic Oncologist, Chief of Heme/Onc @Georgetown University; Head of Developmental Therapeutics @LombardiCancer; Co-Chair #DCLung26 & #TexasLung26; #HereWeGo

Stephen V Liu, MD

@StephenVLiu
DrChoueiri's profile picture. Chief GU Cancers @DanaFarber; Prof Medicine @HarvardMed; ⚽ lover; 🚲@PanMass rider.

Toni Choueiri, MD

@DrChoueiri
PTarantinoMD's profile picture. MD, PhD, Medical Oncologist | Clinical Fellow @DanaFarber | @Harvard. Associate Editor @ESMO_Open. Interested in breast oncology, HER2, ADCs and good music.

Paolo Tarantino

@PTarantinoMD
AndresFCardonaZ's profile picture. Pursue knowledge, mentor students, collaborate globally, and push boundaries. Everything else is just noise in the academic concert.

Andres F. Cardona

@AndresFCardonaZ
UToracica's profile picture. Cuenta oficial del Departamento de Oncología Torácica del Instituto Nacional de Cancerológia de México

UFOT INCan

@UToracica
incanMX's profile picture. El Instituto Nacional de Cancerología es un organismo descentralizado de tercer nivel, dependiente de la Secretaría de Salud.

Instituto Nacional de Cancerología

@incanMX
docramiro's profile picture. Medicina, ciencia y curiosidades. Educación médica.

Ramiro Esparza

@docramiro
OncBrothers's profile picture. Practice changing discussions by community oncologists-Rohit Gosain @RoswellPark & Rahul Gosain @WilmotCancer. OwnViews/NoMedAdvice.COI https://t.co/cJOjp0RvQE

Oncology Brothers

@OncBrothers
HerediaOncologo's profile picture. Oncologo médico. Oncólogo torácico. #INCan 🇲🇽 🫁 Hospital Punta Médica. Candidato SNI. Investigador en ensayos clínicos de cáncer de pulmón.

David Heredia.

@HerediaOncologo
IASLC's profile picture. The International Association for the Study of Lung Cancer is the only global organization dedicated solely to the study of lung cancer. #LCSM

IASLC

@IASLC
MarcelaSaebL's profile picture. derm and dermpath: freedom seeker. opinions my own.

Marcelasaeblima.

@MarcelaSaebL
SMEOMX's profile picture. Asociación no lucrativa dedicada a fomentar, divulgar los avances científicos y la enseñanza de la oncología.

Sociedad Mexicana de Oncología, A.C.

@SMEOMX
andie1306's profile picture. Anestesiología • Música

Señorita Ketamina

@andie1306
IniguezMon's profile picture. Above us only sky. Lo que me gusta le tomo foto.

Mónica

@IniguezMon
drenriquegrande's profile picture. Medical Oncology Department Director at Quironsalud Madrid. Opinions are my own. https://t.co/DrJu4J331O

Enrique Grande

@drenriquegrande
JoeOrricoFF's profile picture. Helping You Win Fantasy Football Leagues || Creator of @NoExpertFF || Join Discord for Answers to All Questions, Rankings, and Bonus Content

Joe Orrico

@JoeOrricoFF
jessicamvasco_'s profile picture. Medical Oncologist at Oncologia D’Or Brasília, Brazil. Former fellow at ICESP USP 🇧🇷

Jéssica Vasconcellos

@jessicamvasco_
FFB_Fanatics's profile picture. The #1 page for everything football. Fantasy/Dynasty Football • Bestball • Prospect Evaluations • Highlights • Updates • Discussions

Football Fanatics

@FFB_Fanatics
mayluciemeyer's profile picture. Swiss medical oncologist, trained in Paris (go PSG) and NY (go Trader Joe)

Meyer May-Lucie

@mayluciemeyer
OncoUNILCHUV's profile picture. Official account of the Department of Oncology UNIL CHUV, Lausanne University Hospital | Ludwig Lausanne Branch, Switzerland

Oncology UNIL CHUV

@OncoUNILCHUV
ElRetoso's profile picture. https://t.co/759qUBoe13

EL RETOSO

@ElRetoso
giulialmironmed's profile picture. 🇧🇷 Final-year medical student || Aspiring Urologist || USMLE Journey || #FirstGen || 🎬🎵🥋🏋️

Giulia Almiron

@giulialmironmed
medcrux's profile picture. 👨‍⚕️ Just a medico helping medicos 📚 Daily MCQs | Clinical Cases | Exam Boosters 🎯 NEET PG | INI-CET | FMGE | USMLE 💙 If My Posts helped you, TIP💸 below ⤵️

MEDCRUX

@medcrux
COlazagasti's profile picture. Doctor, wife & mama! Proud #boricua 🇵🇷 Assistant Professor @ Sylvester Cancer Center. Views are my own

Coral Olazagasti, MD

@COlazagasti
JessicaMenis's profile picture. Medical Oncologist at University Hospital of Verona

Jessica Menis

@JessicaMenis
maraantonoff's profile picture. Assoc Professor Thoracic & Cardiovascular Surgery, MD Anderson Cancer Center, Prez @womeninthoracic #ILookLikeASurgeon #tssmn #lcsm #MedEd #endcancer #ctcareers

Mara Antonoff, MD, FACS

@maraantonoff
pompili_cecilia's profile picture. General Thoracic Surgeon, Associate Professor focusing on patient reported outcomes (PROMs) in lung cancer care @HullYorkMed @ests_womenThor

Cecilia Pompili MD PhD FACS

@pompili_cecilia
nuria_dios's profile picture. Radiation Oncologist. Hospital Clínico Universitario Santiago de Compostela. Diving lover 🤿 🐠

Núria Rodg de Dios

@nuria_dios
AHazimMD's profile picture. Thoracic Medical Oncologist, Assistant Professor @MayoClinic AZ ☀️. Specializing in solid tumor cellular therapies, phase 1 trials, lung cancer 🫁 Views my own

Antonious Z. Hazim, MD

@AHazimMD
PalomaV93622771's profile picture. ✨Esfuérzate y se bien pinche valiente ✨. https://t.co/QxolPpj8hk

Palomita 🫧

@PalomaV93622771
MdWistuba's profile picture. @MoffittNews Department Chair, Translational Pathology. Views are my own.

Ignacio Wistuba, MD

@MdWistuba
UOzkerim's profile picture. Medical Oncologist sharing the pulse of global oncology 🌍 #OncoAlertAF | From data to daily practice 💊 Dog dad 🐶🐾

Uğur Özkerim

@UOzkerim
amtzcannon's profile picture. 🚺 Gynae & Breast Medical Oncologist @incmnszmx | | Gynae Fellow @royalmarsdenNHS | | 💙 Internal Medicine & EMIS 32 @TecSaludMX

Alejandra Martinez-Cannon

@amtzcannon
SergioMonraz's profile picture. -Neumólogo -Alta Especialidad en Fisiología Pulmonar y Terapia Respiratoria. 😷🏥👨🏻‍⚕️ -Especialista Tx del Tabaquismo -Pulmo Channel (Podcast, YouTube)

Dr. Sergio Monraz Pérez. NeumologíaCdMX.

@SergioMonraz
AnnaliceGandini's profile picture.

Annalice Gandini

@AnnaliceGandini
carlacorvaja_'s profile picture. MD

Carla

@carlacorvaja_
FASinicropeMD's profile picture. Professor Med Onc + GI, researcher @MayoClinic. Interests: #colorectalcancer, #GIcancer, #Immunotherapy. #hereditarycancers. Views my own.@FASinicropeMD

Frank Sinicrope, MD

@FASinicropeMD
ONCOassist's profile picture. The go-to app for oncology professionals. Access all the clinical tools & information you need at point of care. CE approved.

ONCOassist® | The go-to oncology app

@ONCOassist
gbanna74's profile picture. Consultant Medical Oncologist for Lung and Urology Cancer aiming to Clinician Scientist #lungcancer #urologycancer. I love my work but my family is my life

Giuseppe Banna

@gbanna74
brunolarvol's profile picture. @LARVOL | 100 experts building onco super intelligence | 200,000 KM curves digitized | free for non-commercial use | ex-IBM

ONCO BRUNO

@brunolarvol
Larvol's profile picture. At the intersection of #AI & #Oncology data. We provide clinical intelligence, trial insights & competitive analysis for #Pharmaceutical & #BioTech.

LARVOL

@Larvol
ozdogan_md's profile picture. Oncologist. Cancer treatment & care in Turkey. Current advances, future directions and second opinion... Let's create a society which is not afraid of cancer!

Mustafa Özdoğan, MD

@ozdogan_md
Dr_Oncologista's profile picture. MSc | MD Oncolog🎗 #breastcancer & Researcher 🧬 |Certified by American and European Boards. Associate lecturer of medical Oncologist• Member of @ASCO | @MyESMO

Aya Mohamed | MSc, MD 🎗

@Dr_Oncologista
DrYujiUehara's profile picture. Medical Oncologist (National Cancer Center Hospital)/Lung cancer, Precision oncology, Early drug development/ JSMO, JLCS social media committee/ @Phase1_NCCH

Yuji Uehara, MD

@DrYujiUehara
KCentelles's profile picture. Breast Medical Oncologist @incanMX. Researcher, joy seeker and lifelong learner 🇲🇽 🦀🧬 ES/EN. Opinions expressed are solely personal.

Karla Centelles

@KCentelles
DrCatharineY's profile picture. Scientist || Immigrant || Senior Fellow @HarvardChanSPH || Fmr: White House #CancerMoonshot, @CornellBME, @TEDFellow || 🇿🇦 + 🇺🇸

Dr. Catharine Young

@DrCatharineY
HHorinouchi's profile picture. Medical Oncologist, @NCCJ_official, @JCOG_official, Education committee @JSMO_official @JLCS_OFFICIAL @IASLC @ASCO FCOI https://t.co/c9VKywUIsh

Hidehito HORINOUCHI

@HHorinouchi
ThomasW35874311's profile picture. I am a doctor

Thomas Wu

@ThomasW35874311
youngkwangchae's profile picture. Medical Oncologist, Translational Physician-Scientist, Professor, Co-Director of Developmental Therapeutics Lurie Cancer Center at Northwestern University

Young Kwang Chae, MD, MPH, MBA

@youngkwangchae
LuisRaezMD's profile picture. Chief Sci Off & Med Dir Memorial Can Inst/Memorial Health Syst Past Pres. FLASCO, old account @luiseraez1 was dc, personal site

Dr. Luis E. Raez

@LuisRaezMD
LochrinSarah's profile picture. Medical Oncology, Ireland.

Sarah E. Lochrin

@LochrinSarah
FedericoCappuz1's profile picture.

Federico Cappuzzo

@FedericoCappuz1
BRicciutiMD's profile picture. Thoracic Medical Oncologist at @DanaFarber | @harvardmed #Immunotherapy #KRAS #BRAF #MET #LungCancer

Biagio Ricciuti, MD, PhD

@BRicciutiMD
stephanieplsaw's profile picture. Medical Oncologist from 🇸🇬

Stephanie Saw

@stephanieplsaw
MichF1Insider's profile picture. Sports Betting Analyst | Pro Formula 1 Bettor 🏎 #KeepPushing Grupo Gratuito en el link ↓

Mich F1

@MichF1Insider
DraDolo's profile picture. Breast Surgeon at @institutoroffo #hereditarycancer #precisionmedicine . Mamaculposade3 #workingmom

Dolo

@DraDolo
ROS1CancerSpain's profile picture. Because everyone deserves the best diagnosis and the best treatment for their disease. #ROS1 advocate. #ROS1agnostic

ROS1 Cancer Spain

@ROS1CancerSpain
TwoOncDocs's profile picture. 🩸 a podcast about heme/onc for health care providers | ☕️ short high yield episodes to supplement your board review resources | @SamArmstrongMD @DrKarineTawagi

TwoOncDocs

@TwoOncDocs
lizbethramos5's profile picture.

lizbeth ramos

@lizbethramos5
DADynasty_'s profile picture. Providing an exhilarating Season-Long series where a group of friends compete to bring home a 🏆 FF Content, Rankings, Orphans, and 24/7 Advice! 🔥

DA Dynasty

@DADynasty_
ConquerCancerFd's profile picture. @ASCO's foundation funding research to conquer every cancer, for every patient, everywhere.

Conquer Cancer, the ASCO Foundation

@ConquerCancerFd
DrScottHaake's profile picture. Excited to learn more about kidney cancer, biomarkers, integrins, and ECM biology. Views expressed are my own, not any institution’s. RT/like not endorsement.

Scott Haake, MD, PhD

@DrScottHaake
lauren_henke's profile picture. GI Rad Onc + Adaptive RT + Residency PD @RadOncUh + @caseccc | via @wustlmed @washuradonc | motivated, caffeinated, oversized heart | opinions ≠ my employer's

Lauren Henke, MD, MSCI

@lauren_henke
NatureRevEndo's profile picture. The latest advances in diabetes, obesity, nutrition, thyroid and more from the editors of Nature Reviews Endocrinology, a review journal.

Nature Reviews Endocrinology

@NatureRevEndo
PopesFFH's profile picture. Dad | Husband | Analyst @FTNFantasy | 🎙️FTN Dynasty Podcast | #SFB15⬅️11| #NFLDraft | #BillsMafia | Beyond the Chalk

Jeremy

@PopesFFH

United States Trends

You might like

Something went wrong.


Something went wrong.